PAVmed Inc PAVM 深 滬
已收盤 08-01 16:00:00 美东时间
0.5254
-0.050
-8.74%
華盛通- 最 高0.5688
- 今 開0.5688
- 成交量 18.59万股
- 最 低 0.5133
- 昨 收 0.5757
- 總市值 908.66万
- 52周最高 1.90
- 市盈率 靜 1.06
- 換手率 1.07%
- 52周最低 0.5133
- 委 比 32.66%
- 總股本 1729.46万
- 歷史最高 228.0532
- 量 比 2.43
- 振 幅 9.64%
- 歷史最低 0.5133
- 每 手 1
- 風險率 0.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PAVmed gets 180-day extension to regain Nasdaq listing compliance
PAVmed (NASDAQ:PAVM) has been granted a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under the Nasdaq listing rule. The company now has until January 19, 2026 to...
07-30 20:16
Preview: Ekso Bionics Holdings's Earnings
Ekso Bionics Holdings (NASDAQ:EKSO) is set to give its latest quarterly earning...
07-26 03:01
Lucid Diagnostics, a PAVmed Subsidiary, Nears Medicare Decision on EsoGuard Cancer Test
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that on
07-16 19:35
PAVmed’s Veris Health Completes $2.5M Offering
An announcement from PAVmed ( ($PAVM) ) is now available. On June 23, 2025, Ver...
06-24 20:46
PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing
Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW YORK, June 24, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PA...
06-24 20:01
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $19
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $19.5 to $19.
06-06 18:29
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of ...
05-27 19:31
PAVmed shares are trading lower after the company reported a year-over-year decrease in Q1 sales results.
PAVmed shares are trading lower after the company reported a year-over-year dec...
05-15 23:51
PAVmed Q1 Adj. EPS $(0.07) Beats $(0.13) Estimate, Sales $8.00K Miss $10.00K Estimate
PAVmed (NASDAQ:PAVM) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.13) by 46.15 percent. This is a 92.93 percent increase over losses of $(0.99) per share from the same
05-15 20:02
